Damage to the brain’s blood vessels accumulates as people age, but scientists still know little about what causes this, much less how to detect or prevent it. A consortium led by scientists at ...

With two amyloid immunotherapies on the market in many countries, scientists are eager for information on how durable their clinical effects will be. At this year’s Alzheimer’s Association ...

CagA disrupts bacterial biofilms. It also prevents Aβ and α-synuclein from forming fibrils. Scientists will test CagA in AD and PD mouse models to assess its therapeutic potential. Scientists estimate ...

Cytotoxic T cells are star players in the adaptive immune system, enforcing protection against invading viruses or cancer cells. However, evidence has been mounting that the cells may also deal a ...

In memory clinics and in research cohorts, immunoassays for plasma markers can now distinguish people who have Alzheimer’s disease pathology with remarkable accuracy (see Part 7 of this series). How ...

Tau PET correlates closely with cognitive decline in Alzheimer’s disease, making it a potential surrogate outcome measure. Yet in amyloid immunotherapy trials to date, this signal has not always ...

At the 19th AD/PD conference, Alzforum reporters wrote 15 summaries of findings across both diseases. From a step toward finally having an α-synuclein PET tracer to a major focus on Trem2 as a drug ...

As the baby boom generation reaches its hopefully golden years, scientists have been projecting a doubling of dementia cases in the U.S. by 2050, alarming health care agencies, the public, and health ...

Missense mutations that derail SORL1 trafficking cause AD. Other variants shift AD risk in East Asians and Europeans. SORL1 dysfunction messes with endosomes in neurons, and with lysosomes in ...

This letter was prompted by your recent perspective paper and the responses it provoked in an Alzforum discussion. Generally, my comments are offered with the intellectual humility required when ...

Just as Eisai notches wins in its campaign for lecanemab approval around the world—last month in the European Union, this week in Mexico—a dozen research and clinical leaders called on the U.S. FDA ...

Fewer than 1 percent of amyloid-targeted monoclonal antibodies like lecanemab and donanemab reach their targets in the brain. The excess doses required to make up for this problem raise the risk of ...